Related Experiment Video
Updated: Jan 24, 2026

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction
Lea Landolt1, Jessica Furriol2, Janka Babickova1
1Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Abstract:
The AXL receptor tyrosine kinase (RTK) is involved in partial epithelial-to-mesenchymal transition (EMT) and inflammation - both main promoters of renal fibrosis development. The study aim was to investigate the role of AXL inhibition in kidney fibrosis due to unilateral ureteral obstruction (UUO). Eight weeks old male C57BL/6 mice underwent UUO and were treated with oral AXL inhibitor bemcentinib (n = 22), Angiotensin-converting enzyme inhibitor (ACEI, n = 10), ACEI and bemcentinib (n = 10) or vehicle alone (n = 22). Mice were sacrificed after 7 or 15 days and kidney tissues were analyzed by immunohistochemistry (IHC), western blot, ELISA, Sirius Red (SR) staining, and hydroxyproline (Hyp) quantification. RNA was extracted from frozen kidney tissues and sequenced on an Illumina HiSeq4000 platform. After 15 days the ligated bemcentinib-treated kidneys showed less fibrosis compared to the ligated vehicle-treated kidneys in SR analyses and Hyp quantification. Reduced IHC staining for Vimentin (VIM) and alpha smooth muscle actin (αSMA), as well as reduced mRNA abundance of key regulators of fibrosis such as transforming growth factor (Tgfβ), matrix metalloproteinase 2 (Mmp2), Smad2, Smad4, myofibroblast activation (Aldh1a2, Crlf1), and EMT (Snai1,2, Twist), in ligated bemcentinib-treated kidneys was compatible with reduced (partial) EMT induction. Furthermore, less F4/80 positive cells, less activity of pathways related to the immune system and lower abundance of MCP1, MCP3, MCP5, and TARC in ligated bemcentinib-treated kidneys was compatible with reduction in inflammatory infiltrates by bemcentinib treatment. The AXL RTK pathway represents a promising target for pharmacologic therapy of kidney fibrosis.
Insights
AXL receptor inhibition with bemcentinib reduced kidney fibrosis and inflammation in mice with unilateral ureteral obstruction. This suggests AXL receptor tyrosine kinase (RTK) is a promising therapeutic target for treating kidney fibrosis.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Renal fibrosis is a major cause of kidney disease progression.
- Epithelial-to-mesenchymal transition (EMT) and inflammation are key drivers of renal fibrosis.
- AXL receptor tyrosine kinase (RTK) signaling is implicated in EMT and inflammation.
Purpose of the Study:
- To investigate the therapeutic potential of AXL inhibition in a mouse model of kidney fibrosis.
- To evaluate the effects of bemcentinib, an AXL inhibitor, on fibrosis and inflammation markers following unilateral ureteral obstruction (UUO).
Main Methods:
- Unilateral ureteral obstruction (UUO) model in C57BL/6 mice.
- Treatment groups included bemcentinib, ACE inhibitor (ACEI), combined ACEI and bemcentinib, and vehicle control.
- Kidney tissues analyzed via immunohistochemistry (IHC), western blot, ELISA, Sirius Red staining, hydroxyproline quantification, and RNA sequencing.
Main Results:
- Bemcentinib treatment significantly reduced kidney fibrosis, as evidenced by Sirius Red staining and hydroxyproline levels.
- AXL inhibition decreased markers of (partial) epithelial-to-mesenchymal transition (EMT), including Vimentin (VIM), alpha smooth muscle actin (αSMA), and key EMT regulators.
- Bemcentinib treatment also reduced inflammatory infiltrates, indicated by lower F4/80 positive cells and inflammatory chemokines (MCP1, MCP3, MCP5, TARC).
Conclusions:
- AXL receptor tyrosine kinase (RTK) signaling blockade with bemcentinib effectively ameliorates kidney fibrosis and associated inflammation.
- AXL RTK inhibition demonstrates significant therapeutic potential for managing kidney fibrosis.
- Targeting the AXL RTK pathway offers a promising strategy for pharmacologic intervention in kidney fibrosis.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Design Example: Measuring Distance Between Two Points with Obstructions

